Literature DB >> 21616116

A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC).

Chad K Porter1, Mark S Riddle, David R Tribble, A Louis Bougeois, Robin McKenzie, Sandra D Isidean, Peter Sebeny, Stephen J Savarino.   

Abstract

Volunteer challenge with enterotoxigenic Escherichia coli (ETEC) has been used for four decades to elucidate the pathogenesis and immune responses and assess efficacy of various interventions. We performed a systematic review of these studies and a meta-analysis of individual patient-level data (IPD) from a subset of studies using standard methodology. We identified 27 studies of 11 ETEC strains administered to 443 naive subjects at doses from 1×10(6) to 1×10(10) colony forming units (cfu). Diarrhea attack rates varied by strain, dose and enterotoxin. Similar rates were seen at doses of 5×10(8) to 1×10(10)cfu with the three most commonly used strains B7A, E24377A, H10407. In IPD analysis, the highest diarrhea attack rates were seen with strains B7A, H10407 and E24377A. The H10407 induced significantly higher stool output than the other strains. Additionally, the rate of output was different across strains. The risk of diarrhea, abdominal cramps, nausea and headaches differed significantly by ETEC strain. An increased risk of nausea, abdominal cramps and headaches was seen for females. Baseline anti-LT IgG titers appeared to be associated with a decrease risk of diarrhea outcomes, a trend not seen with anti-LT IgA or seen consistently with anti-colonization factor antibodies. Neither early antibiotic treatment nor diarrhea duration significantly affected the frequency or magnitude of serologic responses. These studies have served as an invaluable tool in understanding disease course, pathogenicity, innate immune responses and an early assessment of product efficacy. When designing and planning experimental ETEC infection studies in this age of increased ethical scrutiny and growing appreciation of post-infectious sequelae, better understanding of available data is essential. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21616116     DOI: 10.1016/j.vaccine.2011.05.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  Establishment, Validation, and Application of a New World Primate Model of Enterotoxigenic Escherichia coli Disease for Vaccine Development.

Authors:  Julianne E Rollenhagen; Franca Jones; Eric Hall; Ryan Maves; Gladys Nunez; Nereyda Espinoza; Aisling O'Dowd; Michael G Prouty; Stephen J Savarino
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  The effect of a multi-strain probiotic on the resistance toward Escherichia coli challenge in a randomized, placebo-controlled, double-blind intervention study.

Authors:  S J M Ten Bruggencate; S A Girard; E G M Floris-Vollenbroek; R Bhardwaj; T A Tompkins
Journal:  Eur J Clin Nutr       Date:  2014-11-05       Impact factor: 4.016

3.  Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects.

Authors:  David L Evers; Carol B Fowler; Jeffrey T Mason; Rebecca K Mimnall
Journal:  Sci Eng Ethics       Date:  2014-08-24       Impact factor: 3.525

4.  Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.

Authors:  Milton Maciel; David Bauer; Robin L Baudier; Jacob Bitoun; John D Clements; Steven T Poole; Mark A Smith; Robert W Kaminski; Stephen J Savarino; Elizabeth B Norton
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

5.  Establishment and Validation of Pathogenic CS17+ and CS19+ Enterotoxigenic Escherichia coli Challenge Models in the New World Primate Aotus nancymaae.

Authors:  Eric R Hall; Aisling O'Dowd; Julianne E Rollenhagen; Nereyda Espinoza; Gladys Nunez; Stephen J Savarino
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

6.  Murine immunization with CS21 pili or LngA major subunit of enterotoxigenic Escherichia coli (ETEC) elicits systemic and mucosal immune responses and inhibits ETEC gut colonization.

Authors:  Chengxian Zhang; Junaid Iqbal; Oscar G Gómez-Duarte
Journal:  Vet Microbiol       Date:  2016-02-06       Impact factor: 3.293

7.  Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge.

Authors:  Wilson B Luiz; Juliana F Rodrigues; Joseph H Crabb; Stephen J Savarino; Luis C S Ferreira
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

8.  Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in Humans.

Authors:  William E Yang; Sunil Suchindran; Bradly P Nicholson; Micah T McClain; Thomas Burke; Geoffrey S Ginsburg; Clayton D Harro; Subhra Chakraborty; David A Sack; Christopher W Woods; Ephraim L Tsalik
Journal:  J Infect Dis       Date:  2016-01-18       Impact factor: 5.226

9.  Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.

Authors:  Clayton Harro; Subhra Chakraborty; Andrea Feller; Barbara DeNearing; Alicia Cage; Malathi Ram; Anna Lundgren; Ann-Mari Svennerholm; August L Bourgeois; Richard I Walker; David A Sack
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

10.  The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.

Authors:  Michael J Darsley; Subhra Chakraborty; Barbara DeNearing; David A Sack; Andrea Feller; Charlotte Buchwaldt; A Louis Bourgeois; Richard Walker; Clayton D Harro
Journal:  Clin Vaccine Immunol       Date:  2012-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.